

VEOZA is indicated for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause.^{1,2}



Want to learn more
about VEOZA?


DISCOVER VEOZA

Dear {{accFname}} {{accLname}},

This is a direct marketing message Thank you for discussing with me regarding Veoza If there are any questions or if you require additional information , please feel free to contact me I look forward to meeting you soon

VEOZA[™] (fezolinetant) directly targets a source of VMS—specific neurons in the hypothalamus. Give your patients another way to treat the heat of VMS day and night.¹

What VEOZA offers your patients with VMS:



A FIRST-IN-CLASS MECHANISM OF ACTION

VEOZA is not a hormone. It's an NK3 receptor antagonist that directly blocks NKB, a known trigger of VMS, from binding on the KNDy neuron.^{1,3,4}



ESTABLISHED EFFICACY

Patients on VEOZA achieved a statistically significant reduction from baseline in frequency and severity of moderate to severe VMS at weeks 4 and 12 compared to placebo.¹



EVALUATED FOR SAFETY IN 2203 WOMEN

Across the phase 3 studies, the most common adverse reactions ($\geq 3\%$) with VEOZA 45 mg were diarrhoea (3.2%) and insomnia (3.0%).¹



ONCE-DAILY DOSING

The recommended dose of VEOZA is 45 mg taken orally with or without food.¹

KNDy: kisspeptin/neurokinin B/dynorphin, NK3: neurokinin 3, NKB: neurokinin B.

[Please click here for Summary of Product Characteristics for VEOZA™ \(fezolinetant\).](#)

Sincerely,
{{userName}}
{{User.Title}}
Astellas Pharmaceuticals Inc.
{{User.Phone}}
{{User.Email}}

REFERENCES: 1. VEOZA Israel SmPC 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician's Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94. 4. Jayasena CN, Comninou AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flashes in women. Sci Rep (Epub) 02-16-2015.

VEOZA 45mg TAB Abbreviated PI Country: Israel

Full Prescribing Information:

<https://israeldrugs.health.gov.il/#!/medDetails/176%2065%2037787%2099>

VEOZA 45mg (Fezolinetant) 45 mg film coated tablets is available on medical prescription only.

Any suspected adverse event should be reported to the Ministry of Health according to the National Regulation by using an online form:

<https://sideeffects.health.gov.il/>

Adverse events may also be reported to Astellas Pharma International B.V.:
Pharmacovigilance.IL@astellas.com

Further information available upon request from: Astellas Pharma
International B.V., Israel

Date of issue aPI: June 2024

Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
©2024 Astellas Pharma Ltd. All rights reserved. Astellas Pharma International B.V.
Hamelacha 21, Rosh Haayn, Israel | Tel: +972 3 750 1166
MAT-IL-VEO-2024-00018 (07/24)

